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Table 1: Equine  influenza H3 subtype-specific antibodies in 20 equine sera as 
measured by pseudotype virus neutralization assay (PVNA) and single radial 
haemolysis (SRH). Shading used to indicate relative antibody levels of response; SRH 
≤100mm2 light, 100-150mm2 medium, ≥150mm2 dark; PVNA ≤5000 light, ≤10000 medium, 
≥10000 dark. NB: PVNA titres <80 are considered negative. 
INTRODUCTION 
 
The primary protective immune response against equine influenza 
virus infection is generation of neutralising antibodies against the 
surface glycoproteins haemagglutinin (HA) and neuraminidase 
(NA). As for human influenza, measurement of anti-HA antibodies 
is important in field studies and experimental vaccination and 
challenge studies to determine the effectiveness and efficacy , 
respectively, of vaccines. 
The haemagglutination inhibition (HI) test is useful for virus 
characterisation and diagnostic purposes as it is a strain-specific assay. However, high 
levels of inter-lab variation are observed, as a result of which protective antibody levels 
are ill-defined, ranging from titres of 8 to 128 [1, 2]. Furthermore, the test only measures 
inhibition of HA binding to cells. The single radial haemolysis (SRH) assay measures 
complement-mediated haemolysis induced by influenza antibody–antigen complexes.  
SRH can be standardised using reference sera [2, 3] and a clear relationship has been 
demonstrated between pre-challenge antibody levels measured by SRH and protection 
afforded in challenge studies [1, 2]. However, the SRH assay has disadvantages: it is 
relatively cumbersome to perform; requires the use of sheep blood and guinea pig 
complement; and resulting zones of haemolysis have to be measured either using 
specialised equipment or by hand using digital callipers.  
Measurement of virus neutralising (VN) antibodies against equine influenza is rarely 
performed; VN assays in eggs are time-consuming and awkward and the lack of 
cytopathic effect in cells requires a two-step assay in which reduction in virus replication 
is measured by detection of viral protein by ELISA or other assays. 
The use of equine influenza pseudotyped lentiviruses may provide a solution to the 
requirement for a reliable and reproducible assay to assess the level of neutralising 
antibodies to equine influenza in vaccinated or naturally-infected horses. A number of 
avian and human influenza virus subtypes have been pseudotyped and used in such 
serological assays [2, 4–6]. A pseudotype virus has the ‘core’ of one virus (e.g. a 
retrovirus) and outer ‘envelope’ of another (e.g. the HA of influenza virus; Figure 1). The 
core virus has deletions in the genome making it replication-deficient, and harbours a 
transgene (e.g. luciferase). The envelope contains specific proteins from the study virus, 
which permit entry into susceptible target cells. During cell transduction, the pseudotype 
virus (PV) genome becomes integrated in the cell genome and expresses the reporter 
gene. Thus the number of transduced cells can be quantified and the subsequent 
inhibitory effects of antibodies in serum and pseudotype entry determined [2, 4–6]. 
AIM  
 
To develop a pseudotype virus neutralization assay (PVNA) for the measurement of 
neutralising antibodies to H3 subtype equine influenza viruses and compare with a 
standard serological assay (SRH) 
MATERIALS AND METHODS 
Viruses and sera 
Stocks of equine influenza A/Sussex/89 virus were grown in 10-day-old embryonated 
hens’ eggs. Serum samples surplus to diagnostic requirements were obtained from 
donkeys recently inoculated (>80  days prior) with vaccines containing the American-
lineage H3N8 strain A/equine/Newmarket/1/93, the European-lineage H3N8 strain 
A/equine/Newmarket/2/93 in addition to A/equine/Prague/56 (H7N7). The positive 
control was a hyper-immunised experimental pony vaccinated with a number of H3N8 
strains over two decades (A/equine/Suffolk/89, A/equine/Newmarket/1/93, 
A/equine/Newmarket/2/93, A/equine/Ohio/03). Negative control horse sera were 
confirmed  by SRH (kind gift of Dr Ann Cullinane, Irish Equine Centre) 
Generation of H3 pseudotyped virus 
Viral RNA was extracted from allantoic fluid using the QIAmp viral RNA extraction kit 
(Qiagen). The full HA gene was amplified by RT-PCR using custom primers (Invitrogen), 
and cloned into the pI.18 expression plasmid. Influenza pseudotyped lentivirus particles 
expressing a luciferase reporter gene were generated using four-plasmid transfection 
(Fugene6; Promega) into HEK293T cells [3]; pI.18-HA, p8.9-HIV-gag/pol, pCSFLW-Luc and 
a pCAGGS-TMPRSS2 protease plasmid to effect cleavage of the HA (Figure 1). 
 
 
CONCLUSIONS & FUTURE WORK 
 
 TMPRSS2 protease necessary for HA cleavage in PV production 
 The PVNA shows promise for the measurement of neutralising antibody responses. 
Assay correlation was good (r=65%, p=0.0002; Pearson analysis using GraphPad) 
 PVNA and SRH measure different types of antibody responses with differing sensitivity 
 Further development of the assay will include: 
• Assessment of sensitivity/specificity and inter/intra-laboratory variability 
• Definition of a protective titre (sera obtained from vaccination and challenge studies) 
 For further details of current study see [7] below 
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Serological assays 
Pseudotype virus neutralization assays (PVNAs) were performed using a standard 
protocol with HEK293T target cells and Bright-Glo (Promega) for luciferase 
measurement [4]. Serum samples were tested in duplicate. 
The SRH assay was performed as described in the OIE (World Organisation for Animal 
Health) Terrestrial Manual using A/equine/Sussex/89 (H3N8) as antigen 
RESULTS 
 
An equine influenza pseudotype virus was successfully generated and used to assay 20 
post-vaccination equine serum samples (Table 1). 
Figure 1:  Schematic of four-
plasmid system for generating 
equine influenza HA 
pseudotyped virus 
Serum sample PVNA (IC50) SRH (mm
2) 
1 1124 79 
2 1860 0 
3 4521 0 
4 4627 83 
5 4673 112 
6 6136 118 
7 6308 116 
8 7500 100 
9 7637 140 
10 7863 61 
11 8056 118 
12 9179 118 
13 9837 106 
14 10523 58 
15 11768 147 
16 13237 153 
17 17908 170 
18 22843 207 
19 35422 156 
20 46617 181 
Positive control 40824 136 
Negative control 1 ≤80 ≤0.5 
Negative control 2 ≤80 ≤0.5 
